-
Study aim
-
Determining the effect of oral Rosemary hydro-alcoholic extract on chemotherapy induced peripheral neuropathy in patients with metastatic gastrointestinal cancer
-
Design
-
This study is a double-blind randomized controlled clinical trial in which 52 patients are randomly assigned to one of two intervention and control (placebo) groups.
In order to equalize the distribution of the important confounders of gender, age and type of cancer, classes based on these variables are classified, and then they are placed in 2 study groups in a balanced way by block randomization.
-
Settings and conduct
-
Patients referring Shahid Rahimi Hospital for chemotherapy are included in the study after giving written informed consent.
Considering that the contents of the capsules are known only to the main researcher and other people are unaware of its contents. Therefore, both investigators, patients, medical staffs and data analysts are blinded in this study.
-
Participants/Inclusion and exclusion criteria
-
Patients with metastatic gastrointestinal cancer, age over 25 years, consent to participate in the study and receive chemotherapy containing oxaliplatin
Non-entry Criteria: patients with significant kidney and liver function impairment
-
Intervention groups
-
In this study, patients will be randomly assigned to one of two intervention or control groups. In the intervention group, patients are given 500 mg capsules containing rosemary extract and the patient is asked to consume three capsules a day for two months.
In the control group, placebo will be given.
-
Main outcome variables
-
The main outcomes including degree of peripheral neuropathy, intensity of neuropathic pain, tendon reflex, feeling of tremors, murmuring, numbness, quality of life, sensory-motor function of the patient and cognitive impairment.